Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference
11 slides from Edwards Lifesciences's conference presentation, Dec 10, 2020
Slide 1: 2020 Investor Conference: Critical Care
2020 Investor Conference Critical Care
Slide 2: Critical Care improving the quality of care for patients
Critical Care improving the quality of care for patients • Continuing to shift product mix towards Smart Recovery, which has highest growth potential of our product groups • Focusing on three key building blocks to advance Smart Recovery patient penetration from 5% to 15% by 2026 • Deploying right t
Slide 3: We are shifting focus of business to Smart Recovery
We are shifting focus of business to Smart Recovery Will become largest part of our portfolio • Will shift mix towards Smart Recovery, which has highest growth potential • This will lead to Smart Recovery Growth Potential Smart Monitoring becoming largest part of our 20% portfolio • Core monitoring
Slide 4: Three Key Building Blocks for Smart Recovery
Three Key Building Blocks for Smart Recovery 2026 15% penetration 2.7M patients AWARENESS Today 18M patients EVIDENCE could benefit from Smart Recovery 5% penetration TECHNOLOGY 700k patients 14M patients could benefit from Smart Recovery 12/10/2020 4
Slide 5: Having the Right Technologies Deployed in Hospitals
Having the Right Technologies Deployed in Hospitals CAPITAL PLATFORM SENSORS SOFTWARE Hypotension FORE SIGHT Prediction 94 Index (HPI) Acumen IQ Sensor ForeSight Viewfinder HemoSphere Remote View Acumen IQ Cuff Long-term growth can only be accomplished if we have our advanced monitoring platform in
Slide 6: Generating Compelling Clinical Evidence
Generating Compelling Clinical Evidence Intraoperative Hypotension (IOH) Matters Edwards HPI Software Can Reduce IOH without Acumen HPI software with Acumen HPI software Both studies demonstrate IOH linked to: Acute kidney Myocardial 30-day 33 mins injury injury mortality HYPE Trial 76% Decrease in
Slide 7: Creating Awareness for our Products Through Evidence
Creating Awareness for our Products Through Evidence “HPI was high…and 10 minutes later there was hypotension. I didn’t see it coming at all.” – Simon Davies, MD MBChB FRCA “We were able to decrease the rate of hypotension by about 50%, which is quite impressive I think.” – Michael Sander, MD, PhD “
Slide 8: 2021 Global Sales Outlook
2021 Global Sales Outlook Headwinds Tailwinds $800M Reduction in elective Non-cardiac elective procedures $725M procedures rebound Hospital capital budget Impact of clinical constraints evidence on adoption 2021E Critical Care Estimated Global Sales 12/10/2020 8
Slide 9: Executive Summary
Executive Summary • Shift product mix towards higher growth Smart Recovery • Advance Smart Recovery penetration from 5% to 15% • Implement building blocks: technology, evidence, awareness 12/10/2020 9
Slide 10: For Professional Use. CAUTION: Federal (United States) law restricts these devices
For Professional Use. CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices pl
Slide 11: P| PP TN
P| PP TN Re ND, ave Edwards Helping Patients is Our Life’s Work, and, now) pe?
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference on 6ix